Particle.news
Download on the App Store
8 ARTICLES
·
yesterday

GLP-1 Drugs Linked to Lower Cancer Risk and Mortality in New Study

NIH-funded research shows a modest reduction in obesity-related cancer risk and all-cause mortality among diabetic adults using GLP-1 receptor agonists, with notable benefits for women.

Image
FILE - Boxes for the medications Wegovy and Zepbound are arranged for a photograph in California on May 8, 2025. (AP Photo/JoNel Aleccia, file)
FILE - The injectable drug Ozempic is shown, July 1, 2023, in Houston. (AP Photo/David J. Phillip, File)
A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024. REUTERS/Hollie Adams/File Photo

Overview

  • A large observational study involving 170,030 adults with obesity and diabetes found GLP-1 receptor agonists were associated with a 7% lower risk of obesity-related cancers compared to DPP-4 inhibitors.
  • The study also reported an 8% reduction in all-cause mortality for GLP-1 users, with women experiencing the most significant benefits, including a 20% lower risk of death.
  • GLP-1 receptor agonists, such as Ozempic, Wegovy, and Zepbound, were compared to DPP-4 inhibitors, which are not associated with weight loss, to isolate the drugs' potential preventive effects.
  • Researchers emphasized that the study's observational design cannot establish causation, highlighting the need for randomized controlled trials to confirm these findings.
  • The study, funded by the NIH’s National Institute of Diabetes and Digestive and Kidney Diseases, will be presented at the 2025 American Society of Clinical Oncology conference in Chicago.